Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGIC AML
2023-503394-37-00Phase 3Authorised
- Sponsor
- Medical University of Lodz
- Start
- Oct 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of midostaurin, gemtuzumab ozogamicin, venetoclax, cytarabine, cladribine and 1 more in acute myeloid leukemia (AML) (2 arms), sponsored by Medical University of Lodz. Primary endpoint: Event-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
midostauringemtuzumab ozogamicinvenetoclaxcytarabinecladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-503394-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503394-37-00.